<ѻýҕl>Raising the Bar for Myelofibrosis Therapy Developmentѻýҕl> Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint Sep 14, 2020
<ѻýҕl>New Insights Into Radiation-Induced Hair Lossѻýҕl> Total dose and fraction size matter, minoxidil may spur regrowth Aug 05, 2020
<ѻýҕl>Triplet OK'd as First-Line Therapy in Melanomaѻýҕl> Immunotherapy plus targeted combo nets FDA approval in BRAF-mutant population Jul 31, 2020
<ѻýҕl>Alex Trebek, Harry Reid and Their Pancreatic Cancer Treatmentѻýҕl> Exploring a 'triangle offense' against the disease Jul 28, 2020
<ѻýҕl>Survival Effect of pCR Elusive in Breast Cancerѻýҕl> 80% lower risk of recurrence with surrogate endpoint, but link to survival unproven Jul 23, 2020
<ѻýҕl>Older Age Should Not Rule Out Chemo in Breast Cancer Patientsѻýҕl> Providers should consider patient priorities when discussing treatment Jul 17, 2020
<ѻýҕl>Brief Quasi-Fasting Diet Boosts Breast Cancer Chemo Responseѻýҕl> Randomized trial in neoadjuvant setting Jun 28, 2020
<ѻýҕl>New Standard for Relapsed/Refractory Multiple Myeloma?ѻýҕl> Triplet regimen significantly extended median PFS versus doublet in IKEMA study Jun 15, 2020
<ѻýҕl>Second Surgery Gets OS Win in Recurrent Ovarian Cancerѻýҕl> Survival improved by nearly 8 months with cytoreductive surgery at first relapse Jun 02, 2020
<ѻýҕl>Early Palliation: Boon for AML Patients on Intensive Chemoѻýҕl> Intervention led to marked improvements in QoL, mental distress, end-of-life care Jun 02, 2020
<ѻýҕl>New First-Line Standard in Metastatic Bladder Cancerѻýҕl> "High bar to beat" as avelumab maintenance improves median survival by over 7 months May 28, 2020
<ѻýҕl>Avelumab Flops Again in Ovarian Cancerѻýҕl> Another negative phase III trial, now in the first-line setting May 19, 2020
<ѻýҕl>Five Days of G-CSF Adequate for Breast Cancer Chemoѻýҕl> Rate of chemotherapy-induced febrile neutropenia similar to 7- to 10-day regimen May 08, 2020
<ѻýҕl>Honing Chemo Use in Small Breast Tumorsѻýҕl> Clearest survival benefit for 8-10 mm tumors in HR/HER2-positive disease May 03, 2020
<ѻýҕl>Add-On Metformin No Help in Advanced Endometrial Cancerѻýҕl> Trial highlights deep racial disparities in treatment response, survival outcomes Apr 27, 2020
<ѻýҕl>Herceptin Boosts OS in HER2-Positive Uterine Cancerѻýҕl> New data bolster targeted approach for aggressive tumor type Apr 24, 2020
<ѻýҕl>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleedsѻýҕl> Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<ѻýҕl>CRC: Upfront, Re-Introduction of FOLFOXIRI Most Effective, but at What Cost?ѻýҕl> Modest survival improvement comes with side effects, toxicity even in healthiest patients Mar 13, 2020
<ѻýҕl>Bringing Transplant to More Patients With AMLѻýҕl> Conditioning with radiolabeled antibody leads to successful transplantation in 84% of older patients Feb 25, 2020
<ѻýҕl>Myeloablative Therapy Prevails in AML Transplant Studyѻýҕl> Better survival, fewer relapses compared with reduced-intensity conditioning Feb 21, 2020
<ѻýҕl>Shannen Doherty's Stage IV Breast Cancerѻýҕl> "Beverly Hills, 90210" star says she's "petrified" Feb 20, 2020
<ѻýҕl>Bell Ringing Not So Joyous for Cancer Patients?ѻýҕl> Greater treatment-related distress for those who rang bell at end of treatment Feb 10, 2020
<ѻýҕl>Bad News on Anti-HER2 Heart Effectsѻýҕl> Exercise, however, may help improve cardio fitness in breast cancer survivors Jan 15, 2020
<ѻýҕl>Chinese Herbal May Be Chemoprotective Against Colorectal Cancerѻýҕl> Polypectomy patients given the supplement developed fewer colorectal adenomas Jan 13, 2020
<ѻýҕl>Higher Risk of Shingles Seen in Patients With Certain Cancersѻýҕl> Vaccine development may help with prevention of herpes zoster in this population Dec 31, 2019
<ѻýҕl>PD-1 vs PD-L1 Inhibitors: Do Outcomes Differ?ѻýҕl> Meta-analysis suggests they aren't equivalent Dec 27, 2019
<ѻýҕl>Anti-CDK4/6 Fails to Top Chemo in HR-Positive MBCѻýҕl> Similar PFS with chemo, palbociclib plus exemestane or fulvestrant after progression on aromatase inhibitor Dec 13, 2019
<ѻýҕl>Checkpoints Show Different Outcomes in Breast Cancerѻýҕl> Atezolizumab misses complete response benefit in triple negative patients Dec 13, 2019
<ѻýҕl>T-DM1 Falls Short as Less-Toxic Option for Early Breast Cancerѻýҕl> Promising efficacy but higher discontinuation rates and cost likely a deterrent Dec 13, 2019
<ѻýҕl>Edging Closer to OS Benefit With Novel Anti-HER2 Drugѻýҕl> Larger benefit with margetuximab in most common HER2 breast cancer phenotype Dec 12, 2019
<ѻýҕl>New Standard for Metastatic HER2 Breast Cancerѻýҕl> Consistent PFS, OS benefit with combination including oral HER2 inhibitor tucatinib Dec 11, 2019
<ѻýҕl>Survival Bump With Oral AML Maintenanceѻýҕl> Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients Dec 10, 2019
<ѻýҕl>Docetaxel First May Boost Survival in mCRPCѻýҕl> Superior outcomes observed versus approach where chemo follows newer agents Dec 05, 2019
<ѻýҕl>IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCRѻýҕl> Prognostic tool may predict who is likely to achieve a relatively long remission Oct 15, 2019
<ѻýҕl>FCR Still an Option in IGHV-Unmutated CLL?ѻýҕl> Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit Oct 08, 2019
<ѻýҕl>Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancerѻýҕl> Misses primary endpoints but has unexpected key benefit Oct 01, 2019
<ѻýҕl>Ibrutinib's Cardiotoxicity Comes Into Focusѻýҕl> Study identifies new cardiac events linked to so-called targeted therapy Sep 25, 2019
<ѻýҕl>Tx Deintensification Wins in Head and Neck Cancer, But ...ѻýҕl> Only against another less-intensive approach in HPV-positive disease Sep 18, 2019
<ѻýҕl>'Dirtier' Drugs Step Aside in RET-Positive NSCLCѻýҕl> Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
<ѻýҕl>Total Chemo Dose Still Matters in Breast Cancerѻýҕl> Worse survival with cumulative dose Aug 20, 2019